Vizora日本語

ChugaiCHUGAI PHARMACEUTICAL CO., LTD.4519東証プライム医薬品FY ending Dec 2023, consolidated, IFRS

Chugai FY ending Dec 2019 results

Chugai brought in ¥686.2B in revenue.

Out of every ¥100 of sales, about ¥31 is left as operating profit.

Revenue changed +18.4% from the prior year.

What changed from last year

FY ending Dec 2018 → FY ending Dec 2019

Revenue
+18.4%¥579.8B → ¥686.2B
Net income attributable to owners
+70.4%¥92.5B → ¥157.6B
Operating cash flow
+73.5%¥119.1B → ¥206.6B

Where the money goes

FY ending Dec 2018 → FY ending Dec 2019

Where ¥100 of sales goes

For every ¥100 Chugai sells, how much goes where, and how much is kept.

FY ending Dec 2019
Operating costs
¥69
Operating profit
¥31
Net profit kept
¥23

Annual margin trends

Gross margin61.2%
FY ending Dec 2019: 61.2%61.2%FY16FY17FY18FY19
Operating margin30.7%
FY ending Dec 2019: 30.7%30.7%FY16FY17FY18FY19
Net margin23.0%
FY ending Dec 2016: 10.9%10.9%FY ending Dec 2017: 13.6%13.6%FY ending Dec 2018: 16.0%16.0%FY ending Dec 2019: 23.0%23.0%FY16FY17FY18FY19

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (4)

  • EDINET (FSA Japan)

    訂正有価証券報告書－第113期(2023/01/01－2023/12/31)

    ID S100U3VS2024-07-26Open

  • EDINET (FSA Japan)

    有価証券報告書－第112期(2022/01/01－2022/12/31)

    ID S100QH692023-03-30Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第111期(令和3年1月1日－令和3年12月31日)

    ID S100NSNY2022-03-30Open

  • EDINET (FSA Japan)

    有価証券報告書－第110期(令和2年1月1日－令和2年12月31日)

    ID S100KZU52021-03-23Open

Extracted from XBRL: 31 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image